The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Bladder Cancer Clinical Trial

— IMGeS  

Official title:

A Study to Assess the Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy in Patients With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06388720
• Other study ID #: NCC2024-0026
• Status: Recruiting
• Phase: Phase 2
• Start date: April 30, 2024
• Est. completion date: December 31, 2027

Study information

• Verified date: April 2024
• Source: National Cancer Center, Korea
• Contact: Ho Kyung Seo, MD
• Phone: 82-31-920-1678
• Email: seohk[@]ncc.re.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.

Description:

Phase 2 clinical, multi-institutional, open assignment prospective study Primary Outcome Measures: 1-year recurrence-free survival period in high-risk groups after sequential injection of Mitomycin-c 40 mg/20 ml and Gemcitabine 2000 mg/50 ml in non-muscle invasive bladder cancer patients in BCG-free high-risk groups. Secondary Outcome Measures: Progression Free Survival (PFS), Cystectomy free survival (CFS), Cancer specific survival (CSS), Overall survival (OS) and safety after Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml treatment in non-muscle invasive bladder cancer patients in BCG-free high-risk groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: December 31, 2027
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. a patient over the age of 20

2. Patients who are willing and able to complete a written test subject consent/approval for this examination.

3. Patients with histological confirmation of high-risk non-muscle infiltration (T1, high-grade Ta and/or CIS) bladder transition cell cancer. However, according to the definition of EAU guidelines high-risk NMIBC, Ta, low grade, and multiple recurrences of more than 3 cm are included.

4. The most recent bladder examination/TURBT must be performed within 8 weeks before the initial administration of the trial treatment. Patients with high risk NMIBC who received proper BCG treatment but did not respond to BCG

5. Patients who are not eligible for a radical bladder resection or who have refused surgery.

6. Patient who are not being pregnant or breast feeding until the study period.

Exclusion Criteria:

1. Patient diagnosed with muscle-invasive bladder cancer at TURBT

2. If upper urinary tract urothelial cancer is accompanied by imaging

3. If the imaging indicates extravesical involvement (cT3)

4. Imaging shows lymph node metastasis (short-axis 15mm or more) or distant metastasis

5. In a biopsy, non-transitional cell histology is dominant, or only non-transitional cell tissue is present (primary squamous cell carcinoma, primary adenocarcinoma, small cell carcinoma, sarcoma, carcinosarcoma, paraganglioma, melanoma, lymphoma)

6. In the case of receiving systemic cytotoxic chemotherapy for other cancers within 3 years

7. If patient have a history of pelvic radiation therapy for other cancers within 3 years

8. If patient have a history of receiving Mitomycin-c or gemcitabine in the bladder within 3 years. The exception is cases used for the purpose of injection therapy of anticancer drugs in the early bladder cancer

9. If patient has a history of allergy to mitomycin-c or gemcitabine

10. Cystoscopy shows a tumor in the prostate urethra

11. Patients who have participated in studies using clinical trial drugs and are currently receiving clinical trial drugs or who have used clinical trial drugs or clinical trial medical devices within 4 weeks prior to the date of initial treatment

12. After post-cystoscopy/TURBT, the patient received intravesical chemotherapy prior to the start of trial treatment

13. Thrombocytopenia, coagulopathy or bleeding tendency patient.

14. Pregnant or breast-feeding women

15. If patient treated yellow fever vaccine or phenytoin

16. Dysfunction of liver or kidney (GFP=30)

17. If patient undergo severe myelosuppression

18. If patient complicated severe infection

19. If patient definitely diagnosed interstitial lung disease or lung fibrosis by chest X-ray.

20. If patient conduct chest radiotherapy.

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.

Locations

Country	Name	City	State
Korea, Republic of	National Cancer Center	Goyang-si

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Center, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrent free survival in sequential treatment group.	Defined as the time when bladder cancer recurrence was first confirmed by biopsy at the initial TURBT date*, the time of disease progression (see PFS definition), the time of radical bladder resection, the time of bladder cancer metastasis, or the time of bladder cancer death.	1year
Secondary	Progression free survival in sequential treatment group.	defined as the period from the initial TURBT date* to the time when T stage progresses (e.g., Ta>T1, CIS>T1) (PFS1) or muscle invasive bladder cancer (T2 or higher) was first biopsy confirmed (PFS2) or imagingally diagnosed with metastasis to bladder cancer.	1year
Secondary	Cystectomy free survival in sequential treatment group.	Defined as the period from the initial TURBT date* to the time when radical cystomy was performed.	1year
Secondary	cancer specific survival in sequential treatment group.	Duration from initial TURBT date* to the time of death from bladder cancer	1year
Secondary	Overall survival in sequential treatment group.	The period from the initial TURBT date* to the point of death (regardless of cause)	1year
Secondary	Safety of sequential treatment.	The first safety analysis is conducted on test subjects who have developed toxicity in accordance with CTCAE standards. In particular, urinary disorders such as urinary tract infections and acute urination that occurred after injection of drugs into the bladder are evaluated.	2year